Preview

Russian Journal of Biotherapy

Advanced search

FLUORESCENT MODIFICATION OF THE MONOCLONAL ANTIBODIES OLIGOSACCHARIDES BY FLUORESCEIN-5-THIOSEMICARBAZIDE

https://doi.org/10.17650/1726-9784-2019-19-2-39-46

Abstract

Introduction Monoclonal antibodies (Mabs) are a good tool for diagnosing human pathologies. They are used as conjugates with fluorescent and other dyes. The classical approach of creating such conjugates is reduced to chemical reactions using the protein base of the Mab. At the same time, for a number of Mabs, conjugate production is accompanied by embedding the label into the antigen binding site, which leads to a decrease or complete loss of the specific activity of the conjugate. To get out of this situation, the synthesis of fluorescent conjugates by methods of carbohydrate chemistry through spatially distant from the active center oligosaccharides of antibodies is proposed.
Objective To obtain high activity ICO series Mab conjugates based on the reaction of covalent inclusion of the fluorescent label in the oligosaccharide sequence of the Mab.
Materials and methods We used Mab series ICO of high purity. Oligosaccharides Mabs oxidized to aldehyde groups, were subjected to interaction with fluoriscine-5-thiosemicarboside, followed by the reduction of hydrazone derivative borgidrides. The resulting covalent conjugate was investigated in a flow cytometry.
Results The synthesis of a fluorescent conjugate using monoclonal antibodies oligosaccharides was worked out. Modified monoclonal antibodies retain specific binding to target cells inherent in the native antibody. The resulting conjugates remained active for a long time during storage.
Conclusion An alternative method for conjugation of immunofluorescent, allowing to obtain conjugates of high activity, has been developed.

About the Authors

A. S. Grinevich
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478


I. V. Chinareva
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478


O. S. Burova
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478


P. K. Ivanov
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478


References

1. Grossberg L., Pressman D. Modification of arginine in the active sites of antibodies. Biochemistry 1968;7(1):272–9. DOI: 10.1021/bi00841a033.

2. Tawfik D.S., Chap R., Eshhar Z., Green BS. pH on–off switching of antibody-hapten binding by site-specific chemical modification of tyrosine. Protein Eng 1994;7(3):431–4. DOI: 10.1093/protein/7.3.431.

3. Dwek R.A., Lellouch A.C., Wormald M.R. Glycobiology: “the function of sugar in the IgG molecule”. J Anat 1995;187(Pt 2):279–92.

4. Matsumiya S., Yamaguchi Y., Saito J. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 2007;4;368(3):767–79. DOI: 10.1016/j.jmb.2007.02.034.

5. Lund J., Takahashi N., Popplewell A. et al. Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I. Eur J Biochem 2000;267(24):7246–57. DOI: 10.1046/j.1432-1327.2000.01839.x.

6. Гриневич А.С., Краева М.Н., Бурова О.С. и др. Использование олигосахаридов иммуноглобулинов для модификации моноклональных антител. Российский биотерапевтический журнал 2016;15(4):44–8. DOI: 10.17650/1726-9784-2016-15-4- 44-48. [Grinevich A.S., Kraeva M.N., Burova O.S. et al. The use of oligosaccharides of immunoglobulin for modification of monoclonal antibodies. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2016;15(4):44–8. (In Russ.)].

7. Ey P.L., Prowse S.J., Jenkin C.R. Isolation of pure IgG1, IgG2a, and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978;15(7):429–36. DOI: 10.1016/0161-5890(78)90070-6.

8. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;15;227(5259):680–5. DOI: 10.1038/227680a0.

9. Hermanson G.T. Fluorescent Probes. In: Bioconjugate Techniques. 3th Ed. Academic Press, 2013:395–463. DOI: 10.1016/B978-0-12-382239-0.00010-8.

10. Голубцова Н.В., Бурова О.С., Барышников К.А. и др. Моноклональные антитела ICO-406 против антигена CD117. Российский биотерапевтический журнал 2015;14(2):99–104. [Golubtsova N.V., Burova O.S., Baryshnikov K.A. at al. Monoclonal antibodies ICO-406 against the antigen CD117. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2015;14(2):99–104. (In Russ.)].

11. Wolfe C.A., Hage D.S. Studies on the rate and control of antibody oxidation by periodate. Anal Biochem 1995;231(1):123–30. DOI: 10.1006/abio.1995.1511.

12. Al-Mawali A., Pinto A.D., Busaidi. R.A., Al-Zakwani I. Lymphocyte subsets: reference ranges in an age- and gender-balanced population of Omani healthy adults. Cytometry 2013;83(8):739–44. DOI: 10.1002/cyto.a.22322.

13. Vira S., Mekhedov E., Humphrey G. et al. Fluorescent-labeled antibodies: Balancing functionality and degree of labeling. Anal Biochem 2010;402(2):146–50. DOI: 10.1016/j.ab.2010.03.036.


Review

For citations:


Grinevich A.S., Chinareva I.V., Burova O.S., Ivanov P.K. FLUORESCENT MODIFICATION OF THE MONOCLONAL ANTIBODIES OLIGOSACCHARIDES BY FLUORESCEIN-5-THIOSEMICARBAZIDE. Russian Journal of Biotherapy. 2020;19(2):39-46. (In Russ.) https://doi.org/10.17650/1726-9784-2019-19-2-39-46

Views: 394


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9784 (Print)
ISSN 1726-9792 (Online)